Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 746,433 shares traded hands during trading, a decline of 44% from the previous session's volume of 1,344,832 shares.The stock last traded at $4.64 and had previously closed at $4.51.
Autolus Therapeutics Price Performance
The firm has a fifty day moving average price of $3.92 and a two-hundred day moving average price of $4.14. The stock has a market capitalization of $1.25 billion, a P/E ratio of -3.92 and a beta of 2.04. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect that Autolus Therapeutics plc will post -0.84 EPS for the current year.
Institutional Investors Weigh In On Autolus Therapeutics
Large investors have recently made changes to their positions in the company. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at about $43,000. Daiwa Securities Group Inc. grew its stake in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares during the period. Herbst Group LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter valued at about $91,000. Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $100,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $108,000. 72.83% of the stock is currently owned by institutional investors.
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
See Also
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
